Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Oct 24, 2022 4:22pm
128 Views
Post# 35044837

RE:F..ck I'm done with this sh.t

RE:F..ck I'm done with this sh.tI'm not sure IR can or has the responsibility to give you quick responses as it relates to a day's poor stock performance.  Here's what we can be sure of, Joseph Arena would not have purchased those shares last week if he believed the company or the stock price was in jeapordy.  He definitely wouldn't have done it if he had any insight to the possibility Dawn was going to liquidate shares.  Instead, it feels like two positive signals.  One open market purchase and one exercising of stock options without a simultaneous sell.  Maybe we learn Dawn did sell in a few days, but I just cannot believe they would have that lack of foresight.  I wonder if the market misread the options exercise or some AI came to an inaccurate conclusion on the insider trading reporting and triggered the selling?  

Nothing really makes sense.

Biobob wrote: IR person does not respond to query on top of that... 


<< Previous
Bullboard Posts
Next >>